Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptayvv1621

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAplus patent kind codes updated
NEWS 15	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 17	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 19	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 22	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 23	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 24	JAN 29	PHAR reloaded with new search and display fields
NEWS 25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases

NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:42:34 ON 08 FEB 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 17:43:31 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0
DICTIONARY FILE UPDATES: 7 FEB 2007 HIGHEST RN 919834-45-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10560127.str



```
chain nodes :
7  8  9  10  11  12  13  14  15  16  17  18  19  26  27  28  29  30  31  32  33  34
 35  36  37  38  39  40  41  42
ring nodes :
1  2  3  4  5  6  20  21  22  23  24  25
chain bonds :
1-35  2-36  3-38  4-37  5-7  6-34  7-8  8-9  9-10  9-16  10-11  11-12  12-13  13-14
 14-15  16-17  16-18  18-19  19-20  21-42  22-41  23-26  24-40  25-39  26-27  27-28
 27-29  28-32  29-30  29-31  32-33
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  20-21  20-25  21-22  22-23  23-24  24-25
exact/norm bonds :
9-16  16-17  19-20  27-28  29-30  29-31
exact bonds :
1-35  2-36  3-38  4-37  5-7  6-34  7-8  8-9  9-10  10-11  11-12  12-13  13-14
14-15  16-18  18-19  21-42  22-41  23-26  24-40  25-39  26-27  27-29  28-32  32-33
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  20-21  20-25  21-22  22-23  23-24  24-25


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:CLASS  27:CLASS
28:CLASS  29:CLASS  30:CLASS  31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS
36:CLASS  37:CLASS  38:CLASS  39:CLASS  40:CLASS  41:CLASS  42:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 full
FULL SEARCH INITIATED 17:44:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      101 TO ITERATE

100.0% PROCESSED      101 ITERATIONS                                  15 ANSWERS
SEARCH TIME: 00.00.01

L2           15 SEA SSS FUL L1

=> d l2 scan

L2   15 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-
     oxoethoxy]-, (αS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI)
MF   C27 H37 N O5 . C4 H11 N

     CM   1

Absolute stereochemistry.
```



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L2 15 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with N,N'-bis(phenylmethyl)-1,2-ethanediamine (1:1) (9CI)
MF C27 H37 N O5 . C16 H20 N2

CM 1

Absolute stereochemistry.



CM 2



L2 15 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI)
MF C27 H37 N O5 . C4 H11 N O3

CM 1

Absolute stereochemistry.



CM 2



L2 15 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, calcium salt, (αS)- (9CI)
MF C27 H37 N O5 . 1/2 Ca

Absolute stereochemistry.



●1/2 Ca

L2 15 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (αS)-α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]benzenepropanoic acid (1:1) (9CI)
MF C27 H36 N O5 . C5 H14 N O

CM 1

Absolute stereochemistry.



CM 2

$Me_3{}^+N-CH_2-CH_2-OH$

L2 15 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, ion(1-), (αS)- (9CI)
MF C27 H36 N O5
CI COM

Absolute stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.55	172.97

FILE 'CAPLUS' ENTERED AT 17:44:44 ON 08 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 8 Feb 2007 VOL 146 ISS 7
FILE LAST UPDATED: 7 Feb 2007 (20070207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3 7 L2

=> d l3 ibib abs hitstr

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:61504 CAPLUS
TITLE: Preparation of phenylpropionic acid derivatives and pharmaceutical compositions thereof
INVENTOR(S): Bjoerk, Seth
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 57pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007008156	A1	20070118	WO 2006-SE864	20060710

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: SE 2005-1644 A 20050711
GI



I



II

AB The title phenylpropionic acid derivs. I [wherein n = 1-2; R1 = H, Cl, CF3, or OCF3; R2 = H or F; R3 = alkyl] or tert-butylamine salts thereof were prepared as PPAR active compds. for treatment of metabolic syndrome including type 2 diabetes mellitus (no data). For example, II and II•tert-butylamine were prepared in a multi-step synthesis. Pharmaceutical compns. were described.

IT 549532-36-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phenylpropionic acid derivs. and pharmaceutical compns. thereof)

RN 549532-36-7 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 549532-35-6P 810676-90-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpropionic acid derivs. and pharmaceutical compns. thereof)

RN 549532-35-6 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 810676-90-5 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:61504 CAPLUS
TITLE: Preparation of phenylpropionic acid derivatives and pharmaceutical compositions thereof
INVENTOR(S): Bjoerk, Seth
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 57pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1.
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007008156	A1	20070118	WO 2006-SE864	20060710

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: SE 2005-1644 A 20050711
GI



I



II

AB The title phenylpropionic acid derivs. I [wherein n = 1-2; R1 = H, Cl,

CF3, or OCF3; R2 = H or F; R3 = alkyl] or tert-butylamine salts thereof were prepared as PPAR active compds. for treatment of metabolic syndrome including type 2 diabetes mellitus (no data). For example, II and II•tert-butylamine were prepared in a multi-step synthesis. Pharmaceutical compns. were described.

IT 549532-36-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phenylpropionic acid derivs. and pharmaceutical compns. thereof)

RN 549532-36-7 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 549532-35-6P 810676-90-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpropionic acid derivs. and pharmaceutical compns. thereof)

RN 549532-35-6 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 810676-90-5 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 75-64-9
CMF C4 H11 N



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:605020 CAPLUS
DOCUMENT NUMBER: 145:83115
TITLE: Preparation of tris(hydroxymethyl)methylamine and ethanolamine salts of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid for treating lipid disorders
INVENTOR(S): Booth, Rebecca J.; Dahlstroem, Mikael
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006065214	A1	20060622	WO 2005-SE1916	20051214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: SE 2004-3072 A 20041216
GI



I

AB The invention relates to a compound selected from one or more of the following: a tris(hydroxymethyl)methylamine salt or an ethanolamine salt of title compound I or a pharmaceutical composition comprising the compound Thus I was prepared in 4 steps from Et (S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate, benzyl bromoacetate, and N-hexyl-2-phenylethylamine. X-ray powder diffration patterns for bot salts of I are given. Both salts have an EC50 of less than 0.5 μmol/l for PPARα.

IT 892402-12-9P 892402-13-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline tris(hydroxymethyl)methylamine and ethanolamine salts
of (2S)-2-ethoxy-3-[4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl]propanoic acid for treating lipid disorders)

RN 892402-12-9 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 892402-13-0 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with aminomethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 3088-27-5
CMF C H5 N O

H_2N-CH_2-OH

IT 549532-35-6P 549532-36-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of crystalline tris(hydroxymethyl)methylamine and ethanolamine salts
of (2S)-2-ethoxy-3-[4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl]propanoic acid for treating lipid disorders)

RN 549532-35-6 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549532-36-7 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1335635 CAPLUS
DOCUMENT NUMBER: 144:69628
TITLE: Preparation of phenoxyacetamide derivatives as modulators of peroxisome proliferator-activated receptors (PPAR)
INVENTOR(S): Alstermark, Eva-Lotte Lindstedt; Olsson, Anna Christina; Li, Lanna
PATENT ASSIGNEE(S): Swed.
SOURCE: U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 499,261.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005282822	A1	20051222	US 2004-26806	20041230
WO 2003051821	A1	20030626	WO 2002-GB5738	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003051822	A1	20030626	WO 2002-GB5744	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1896045	A	20070117	CN 2006-10007173	20021218
WO 2004056748	A1	20040708	WO 2003-GB5602	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004113270	A2	20041229	WO 2004-EP6597	20040617
WO 2004113270	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1676833	A1	20060705	EP 2006-5766	20040617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2005336209	A	20051208	JP 2005-235794	20050816
JP 2006045240	A	20060216	JP 2005-253346	20050901
JP 2006298924	A	20061102	JP 2006-123399	20060427
JP 2006298925	A	20061102	JP 2006-139673	20060519

PRIORITY APPLN. INFO.:

SE 2001-4334	A	20011219
WO 2002-GB5738	W	20021218
WO 2002-GB5744	A	20021218
GB 2002-29931	A	20021221
GB 2003-14079	A	20030618
WO 2003-GB305602	A	20031219
WO 2004-EP6597	A	20040617
US 2005-499261	A2	20050304
CN 2002-828123	A3	20021218
JP 2003-552709	A3	20021218
JP 2003-552710	A3	20021218
JP 2004-561668	A3	20031219
EP 2004-740044	A3	20040617
JP 2006-515989	A3	20040617

OTHER SOURCE(S): MARPAT 144:69628

GI



I

AB The phenyl-, phenoxy-, or phenylthioalkanamidetitle compds., (in particular phenoxyacetamide derivs.) (I) [A is situated in the ortho, meta or para position and represents CR3R4CR1R2COR, CR3:CR1COR (wherein R = H, alkyl, (un)substituted HO or NH2; R1 = alkyl, aryl, alkenyl, alkynyl, or when A is CR3R4CR1R2COR, R1 can also be cyano, (un)substituted HO, SH, OCONH2, SO2NH2, CO2H, etc.; R2 = H, halogen, alkyl, aryl, alkylaryl; R3, R4 = H, alkyl, aryl, alkylaryl); Y = O, S, a single bond; n = an integer of 1-4; X = alkyl; R5, R6 = H, each (un)substituted C1-13 alkyl, C2-10 alkenyl, or C2-10 alkynyl; or R5, R6 = each (un)substituted C3-8 cycloalkyl, C3-C8 cycloalkenyl, aryl, heterocyclyl, or heteroaryl; or R5 and R6 together with the nitrogen atom to which they are attached form a single or a fused heterocyclic system] are prepared These compds. are useful in treating clin. conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, and other manifestations of the metabolic syndrome. Thus, a solution of 0.598 g N-butyl-N-[2-fluoro-4-(trifluoromethyl)benzyl]amine and 0.593 g [4-((2S)-2,3-diethoxy-3-oxopropyl)phenoxy]acetic acid in 20 mL CH2Cl2 was treated with 0.80 mL N,N-diisopropylethylamine and 0.674 g O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate and the reaction mixture was stirred at room temperature overnight to give, after workup and silica gel chromatog., 74% Et (2S)-3-[4-[2-[butyl[2-fluoro-4-(trifluoromethyl)benzyl]amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoate (II). A solution of 0.748 g II in 70 mL MeCN was treated with 35 mL 0.10 M LiOH and the reaction mixture was stirred at room temperature overnight, neutralized with 5% HCl, concentrated, acidified with 5% HCl, and extracted with

EtOAc to give 97% (2S)-3-[4-[2-[butyl[2-fluoro-4-(trifluoromethyl)benzyl]amino]-2-oxoethoxy]phenyl]-2-ethoxypropanoic acid (III). III showed EC50 of 0.001 μmol/L for human PPARα.

IT 549532-36-7P, Ethyl (2S)-2-ethoxy-3-[4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl]propanoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phenoxyacetamide derivs. as modulators of peroxisome proliferator-activated receptors for treating metabolic disorder)

RN 549532-36-7 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 549532-35-6P, (2S)-2-Ethoxy-3-[4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]phenyl]propanoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxyacetamide derivs. as modulators of peroxisome proliferator-activated receptors for treating metabolic disorder)

RN 549532-35-6 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1127321 CAPLUS

DOCUMENT NUMBER: 142:49239

TITLE: Pharmaceutically useful salts (2S)-2-ethoxy-3-(4-{2[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid, preparation thereof, and therapeutic use

INVENTOR(S): Ragnar, Ralf; Stahle, Erica

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004110985	A1	20041223	WO 2004-SE965		20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004247611	A1	20041223	AU 2004-247611		20040616
CA 2527608	A1	20041223	CA 2004-2527608		20040616
EP 1638921	A1	20060329	EP 2004-736956		20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004011455	A	20060718	BR 2004-11455		20040616
CN 1805922	A	20060719	CN 2004-80016838		20040616
JP 3836498	B2	20061025	JP 2006-517040		20040616
JP 2006527767	T	20061207			
US 2006194879	A1	20060831	US 2005-560127		20051209
NO 2005005923	A	20060106	NO 2005-5923		20051213
PRIORITY APPLN. INFO.:			GB 2003-14136	A	20030618
			WO 2004-SE965	W	20040616

AB The invention discloses a calcium or magnesium salt of (2S)-2-ethoxy-3-(4-{2[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid. Compds. of the invention (preparation included) may be used to treat e.g. dyslipidemia and type 2 diabetes.

IT 549532-35-6DP, complexes with magnesium
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
((2S)-2-ethoxy-3-(4-{2[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid salts, preparation, and therapeutic use)

RN 549532-35-6 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 810672-00-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
((2S)-2-ethoxy-3-(4-{2[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid salts, preparation, and therapeutic use)

RN 810672-00-5 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, calcium salt, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

IT 549532-35-6P 549532-36-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
((2S)-2-ethoxy-3-(4-{2[hexyl(2-phenylethyl)amino]-2-oxoethoxy}phenyl)propanoic acid salts, preparation, and therapeutic use)
RN 549532-35-6 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549532-36-7 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1127320 CAPLUS
DOCUMENT NUMBER: 142:49238
TITLE: Pharmaceutically useful salts of (2S)-2-ethoxy-3-[4-(2-(hexyl(2-phenylethyl)amino)-2-oxoethoxy)phenyl]propanoic acid, their preparation, and their therapeutic use
INVENTOR(S): Aurell, Carl-Johan; Dahlstroem, Mikael; Lindstedt-Alstermark, Eva-Lotte; Minidis, Anna; Ohlsson, Bengt; Stahle, Erica
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004110984	A1	20041223	WO 2004-SE964		20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004247610	A1	20041223	AU 2004-247610		20040616
CA 2528932	A1	20041223	CA 2004-2528932		20040616
EP 1638922	A1	20060329	EP 2004-749009		20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
CN 1809529	A	20060726	CN 2004-80016948		20040616
BR 2004011525	A	20060801	BR 2004-11525		20040616
JP 3822900	B2	20060920	JP 2006-517039		20040616
JP 2006527766	T	20061207			
NO 2005005922	A	20060106	NO 2005-5922		20051213
US 2006142389	A1	20060629	US 2005-560657		20051213
PRIORITY APPLN. INFO.:			GB 2003-14129	A	20030618
			WO 2004-SE964	W	20040616

AB The invention discloses salts of (2S)-2-ethoxy-3-[4-(2-(hexyl(2-phenylethyl)amino)-2-oxoethoxy)phenyl]propanoic acid e.g. the L-arginine salt. Preparation of compds. of the invention is described. The compds. of the invention are useful in the treatment of e.g. dyslipidemias and other manifestations of the metabolic syndrome.

IT 810676-88-1P 810676-89-2P 810676-90-5P
810676-93-8P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Pharmaceutically useful salts of (2S)-2-ethoxy-3-[4-(2-(hexyl(2-phenylethyl)amino)-2-oxoethoxy)phenyl]propanoic acid, their preparation, and their therapeutic use)

RN 810676-88-1 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with (1R,2S)-1-amino-2,3-dihydro-1H-inden-2-ol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 136030-00-7
CMF C9 H11 N O

Absolute stereochemistry. Rotation (+).



RN 810676-89-2 CAPLUS
CN L-Arginine, mono[(αS)-α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]benzenepropanoate] (9CI) (CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 810676-90-5 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with 2-methyl-2-propanamine (1:1) (9CI)

(CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 75-64-9
CMF C4 H11 N



RN 810676-93-8 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with N-(phenylmethyl)benzeneethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 3647-71-0
CMF C15 H17 N



IT 810676-91-6 810676-92-7 810676-94-9
810676-96-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Pharmaceutically useful salts of (2S)-2-ethoxy-3-[4-(2-(hexyl(2-phenylethyl)amino)-2-oxoethoxy)phenyl]propanoic acid, their preparation, and their therapeutic use)

RN 810676-91-6 CAPLUS

CN Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with (αS)-α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 810676-95-0
CMF C27 H36 N O5

Absolute stereochemistry.



CM 2

CRN 62-49-7
CMF C5 H14 N O



RN 810676-92-7 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with tricyclo[3.3.1.13,7]decan-1-amine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 768-94-5
CMF C10 H17 N



RN 810676-94-9 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)-, compd. with N,N'-bis(phenylmethyl)-1,2-ethanediamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 549532-35-6
CMF C27 H37 N O5

Absolute stereochemistry.



CM 2

CRN 140-28-3
CMF C16 H20 N2



RN 810676-96-1 CAPLUS
CN Methanaminium, 1-hydroxy-N,N-bis(hydroxymethyl)-N-methyl-, salt with (αS)-α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]benzenepropanoic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 810676-95-0
CMF C27 H36 N O5

Absolute stereochemistry.



CM 2

CRN 14433-29-5
CMF C4 H12 N O3



IT 549532-35-6P 549532-36-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Pharmaceutically useful salts of (2S)-2-ethoxy-3-[4-(2-(hexyl(2-phenylethyl)amino)-2-oxoethoxy)phenyl]propanoic acid, their preparation, and their therapeutic use)
RN 549532-35-6 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 549532-36-7 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1127318 CAPLUS
DOCUMENT NUMBER: 142:56001
TITLE: Preparation of (2S)-3-(4-{2-[amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid derivatives
INVENTOR(S): Aurell, Carl-Johan; Macedo, Emmanuel; Minidis, Anna; Yousefi-Salakdeh, Esmail
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004110982	A1	20041223	WO 2004-SE966		20040616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004247612	A1	20041223	AU 2004-247612		20040616
CA 2528933	A1	20041223	CA 2004-2528933		20040616
EP 1638920	A1	20060329	EP 2004-736958		20040616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR					
CN 1809528	A	20060726	CN 2004-80017131		20040616
BR 2004011558	A	20060801	BR 2004-11558		20040616
JP 3822901	B2	20060920	JP 2006-517041		20040616
JP 2006527768	T	20061207			
NO 2005005924	A	20060105	NO 2005-5924		20051213
US 2006142392	A1	20060629	US 2005-560764		20051213
PRIORITY APPLN. INFO.:			GB 2003-14134	A	20030618
			WO 2004-SE966	W	20040616

OTHER SOURCE(S): MARPAT 142:56001

GI



I

AB The present invention provides a process for preparation of the title compds. I (R = H, R1 = n-C6H13) by reacting I (R = H, or protecting group, R1 = H) with C6H13X (X = leaving group) in the presence of a base and inert solvent at a temperature in the range -25°C to 150°C and optionally, when OR represents a protecting group, removal of the protecting group.

IT 549532-35-6P 810677-36-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(asym. preparation of (2S)-ethoxy[[[hexyl(phenethyl)amino]oxoethoxy]phenyl]propanoic acid)

RN 549532-35-6 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 810677-36-2 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:491168 CAPLUS
DOCUMENT NUMBER: 139:69049
TITLE: Preparation of substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)
INVENTOR(S): Alstermark Lindstedt, Eva-Lotte; Olsson, Anna Christina; Li, Lanna
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051821	A1	20030626	WO 2002-GB5738	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2470491	A1	20030626	CA 2002-2470491	20021218
AU 2002366315	A1	20030630	AU 2002-366315	20021218
EP 1458673	A1	20040922	EP 2002-804964	20021218
EP 1458673	B1	20060906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014988	A	20041214	BR 2002-14988	20021218

HU 200402133	A2	20050228	HU 2004-2133		20021218
CN 1620422	A	20050525	CN 2002-828123		20021218
CN 1620423	A	20050525	CN 2002-828155		20021218
US 2005171204	A1	20050804	US 2003-499261		20021218
JP 2005526011	T	20050902	JP 2003-552709		20021218
JP 3784804	B2	20060614			
TW 253444	B	20060421	TW 2002-91136518		20021218
NZ 533276	A	20060428	NZ 2002-533276		20021218
TW 255807	B	20060601	TW 2002-91136519		20021218
AT 338743	T	20060915	AT 2002-804964		20021218
CN 1896045	A	20070117	CN 2006-10007173		20021218
ZA 2004004657	A	20050829	ZA 2004-4657		20040611
ZA 2004004658	A	20060222	ZA 2004-4658		20040611
NO 2004003023	A	20040715	NO 2004-3023		20040715
US 2005282822	A1	20051222	US 2004-26806		20041230
JP 2005336209	A	20051208	JP 2005-235794		20050816
JP 2006298924	A	20061102	JP 2006-123399		20060427
PRIORITY APPLN. INFO.:			SE 2001-4334	A	20011219
			CN 2002-828123	A3	20021218
			JP 2003-552709	A3	20021218
			JP 2003-552710	A3	20021218
			WO 2002-GB5738	W	20021218
			WO 2002-GB5744	A	20021218
			GB 2002-29931	A	20021221
			GB 2003-14079	A	20030618
			WO 2003-GB305602	A	20031219
			WO 2004-EP6597	A	20040617
			US 2005-499261	A2	20050304

OTHER SOURCE(S): MARPAT 139:69049

GI



I

AB The S enantiomer of I, n = 1 or 2, (C6H13 = hexyl) as well as their pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs are synthesized using various solvents and in presence of charcoal-supported palladium catalyst. The utility of these compds. in clin. conditions such as lipid disorders (dyslipidemias) whether or not associated with insulin resistance and therapeutic and other pharmaceutical activities is also investigated. For example, (2S)-3-(4{2-[benzyl(hexyl)amino]-2-oxoethoxy}phenyl)2-ethoxypropionic acid was prepared in 58% yield via reaction of (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate and benzyl bromoacetate.

IT 549532-35-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of enantiomeric substituted phenylpropionic acid derivs. as agonists to human peroxisome proliferator-activated receptor)

RN 549532-35-6 CAPLUS

CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 549532-36-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of enantiomeric substituted phenylpropionic acid derivs. as agonists to human peroxisome proliferator-activated receptor)
RN 549532-36-7 CAPLUS
CN Benzenepropanoic acid, α-ethoxy-4-[2-[hexyl(2-phenylethyl)amino]-2-oxoethoxy]-, ethyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 17:53:44 ON 08 FEB 2007